{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:20:58Z","timestamp":1790011258417,"version":"4.0.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118192","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:22:18Z","timestamp":1758576138000},"page":"118192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Design and synthesis of novel cyclin-dependent kinase 4\/6(CDK4\/6) and histone deacetylase (HDAC) dual inhibitors: In vitro and in vivo anticancer activity"],"prefix":"10.1016","volume":"301","author":[{"given":"Bongsu","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra","family":"kantha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonku","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3350-1595","authenticated-orcid":false,"given":"Jayaprakash","family":"Neerasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunsuk","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118192_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2025.118192_bib2","volume":"vol. 17","author":"Bhullar","year":"2018"},{"key":"10.1016\/j.ejmech.2025.118192_bib3","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.semcancer.2020.11.013","article-title":"Molecular targets of tyrosine kinase inhibitors in thyroid cancer","volume":"79","author":"Fallahi","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2025.118192_bib4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.118192_bib5","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1080\/14737140.2018.1527688","article-title":"A comprehensive review of protein kinase inhibitors for cancer therapy","volume":"18","author":"Kannaiyan","year":"2018","journal-title":"Expet Rev. Anticancer Ther."},{"key":"10.1016\/j.ejmech.2025.118192_bib6","article-title":"A review on the role of cyclin dependent kinases in cancers","volume":"22","author":"Ghafouri-Fard","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.ejmech.2025.118192_bib7","article-title":"Cyclin-dependent kinases in DNA damage response","volume":"1877","author":"Kciuk","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.ejmech.2025.118192_bib8","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.3390\/ijms22062806","article-title":"Inhibitors of cyclin-dependent kinases: types and their mechanism of action","volume":"22","author":"\u0141ukasik","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118192_bib9","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.3390\/ijms22062935","article-title":"Cyclin-dependent kinases (CDK) and their role in diseases development\u2013review","volume":"22","author":"\u0141ukasik","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118192_bib10","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.3390\/cancers14143380","article-title":"The role of CDK pathway dysregulation and its therapeutic potential in soft tissue sarcoma","volume":"14","author":"Thiel","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.118192_bib11","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1038\/s41388-022-02347-1","article-title":"Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer","volume":"41","author":"Constantin","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118192_bib12","doi-asserted-by":"crossref","DOI":"10.1186\/s13058-015-0661-5","article-title":"Targeting the cyclin-dependent kinases (CDK) 4\/6 in estrogen receptor-positive breast cancers","volume":"18","author":"Finn","year":"2016","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118192_bib13","doi-asserted-by":"crossref","first-page":"10131","DOI":"10.1074\/jbc.M116.773226","article-title":"CDK4 protein is degraded by anaphase-promoting complex\/cyclosome in mitosis and reaccumulates in early G1phase to initiate a new cell cycle in HeLa cells","volume":"292","author":"Chen","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118192_bib14","article-title":"Cyclin D\/CDK4\/6 activity controls G1 length in mammalian cells","volume":"13","author":"Dong","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118192_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/srep35383","article-title":"CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer","volume":"6","author":"Dai","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118192_bib16","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1158\/1078-0432.CCR-14-2955","article-title":"CDK4 amplification reduces sensitivity to CDK4\/6 inhibition in fusion-positive rhabdomyosarcoma","volume":"21","author":"Olanich","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118192_bib17","doi-asserted-by":"crossref","first-page":"6479","DOI":"10.3390\/ijms21186479","article-title":"Targeting cell cycle in breast cancer: CDK4\/6 inhibitors","volume":"21","author":"Piezzo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118192_bib18","article-title":"Selective inhibition of CDK4\/6: a safe and effective strategy for developing anticancer drugs","author":"Yuan","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.118192_bib19","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-015-0369-5","article-title":"Targeted therapies for ER+\/HER2- metastatic breast cancer","volume":"13","author":"Yamamoto-Ibusuki","year":"2015","journal-title":"BMC Med."},{"key":"10.1016\/j.ejmech.2025.118192_bib20","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/gutjnl-2016-312268","article-title":"Palbociclib (PD-0332991), a selective CDK4\/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma","volume":"66","author":"Bollard","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.ejmech.2025.118192_bib21","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3390\/cancers16081555","article-title":"CDK inhibitors and FDA: approved and orphan","volume":"16","author":"Cicenas","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.118192_bib22","first-page":"1","article-title":"Recent progress of CDK4\/6 inhibitors' current practice in breast cancer","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ejmech.2025.118192_bib23","doi-asserted-by":"crossref","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.ejmech.2025.118192_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","article-title":"The role of histone deacetylases (HDACs) in human cancer","volume":"1","author":"Ropero","year":"2007","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118192_bib25","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1615\/CritRevOncog.2015012997","article-title":"Histone deacetylases and mechanisms of regulation of gene expression","volume":"20","author":"Chen","year":"2015","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.ejmech.2025.118192_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/s12958-020-00637-5","article-title":"Histone acetylation and the role of histone deacetylases in normal cyclic endometrium","volume":"18","author":"Gujral","year":"2020","journal-title":"Reprod. Biol. Endocrinol."},{"key":"10.1016\/j.ejmech.2025.118192_bib27","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.12659\/MSM.904597","article-title":"Histone deacetylase (HDAC) inhibitor, suberoylanilide Hydroxamic acid (SAHA), induces apoptosis in prostate cancer cell lines via the Akt\/FOXO3a signaling pathway","volume":"23","author":"Shi","year":"2017","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.ejmech.2025.118192_bib28","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.14889","article-title":"Recent developments of HDAC inhibitors: emerging indications and novel molecules","volume":"87","author":"Bondarev","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118192_bib29","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.3390\/ijms18071414","article-title":"Histone deacetylase inhibitors as anticancer drugs","volume":"18","author":"Eckschlager","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118192_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101312","article-title":"HDAC inhibitors: targets for tumor therapy, immune modulation and lung diseases","volume":"16","author":"Shanmugam","year":"2022","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.ejmech.2025.118192_bib31","doi-asserted-by":"crossref","first-page":"128797","DOI":"10.1016\/j.bmcl.2022.128797","article-title":"Comparison of three zinc binding groups for HDAC inhibitors \u2013 a potency, selectivity and enzymatic kinetics study","volume":"70","author":"Yue","year":"2022","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2025.118192_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104801","article-title":"Discovery of novel tetrahydrobenzo[b]thiophene-3-carbonitriles as histone deacetylase inhibitors","volume":"110","author":"Gediya","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118192_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.sbi.2019.01.004","article-title":"Structure, mechanism, and inhibition of the zinc-dependent histone deacetylases","volume":"59","author":"Porter","year":"2019","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.ejmech.2025.118192_bib34","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.embor.7401047","article-title":"Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8\u2013substrate complex","volume":"8","author":"Vannini","year":"2007","journal-title":"EMBO Rep."},{"key":"10.1016\/j.ejmech.2025.118192_bib35","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","article-title":"Mechanisms of sensitivity and resistance to CDK4\/6 inhibition","volume":"37","author":"\u00c1lvarez-Fern\u00e1ndez","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.118192_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.03.068","article-title":"Cdk4 and Cdk6 couple the cell-cycle machinery to cell growth via mTORC1","volume":"31","author":"Romero-Pozuelo","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2025.118192_bib37","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1128\/MCB.23.8.2669-2679.2003","article-title":"The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21\/WAF1\/CIP1 gene","volume":"23","author":"Lagger","year":"2003","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118192_bib38","doi-asserted-by":"crossref","first-page":"6174","DOI":"10.18632\/oncotarget.23485","article-title":"Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma","volume":"9","author":"Heijkants","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.118192_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112073","article-title":"Discovery of novel cyclin-dependent kinase (CDK) and histone deacetylase (HDAC) dual inhibitors with potent in vitro and in vivo anticancer activity","volume":"189","author":"Cheng","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118192_bib40","doi-asserted-by":"crossref","first-page":"15220","DOI":"10.1021\/acs.jmedchem.4c00837","article-title":"Discovery of novel 2-Aminopyridine-Based and 2-Aminopyrimidine-Based derivatives as potent CDK\/HDAC dual inhibitors for the treatment of refractory solid tumors and hematological malignancies","volume":"67","author":"Saidahmatov","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118192_bib41","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1021\/acs.jmedchem.8b00209","article-title":"Discovery of N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d]pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide as a novel inhibitor targeting cyclin-dependent kinase 4\/9 (CDK4\/9) and histone Deacetlyase1 (HDAC1) against malignant cancer","volume":"61","author":"Li","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118192_bib42","doi-asserted-by":"crossref","first-page":"112322","DOI":"10.1016\/j.ejmech.2020.112322","article-title":"Design, synthesis and biological evaluation of novel histone deacetylase1\/2 (HDAC1\/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer","volume":"198","author":"Yun","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118192_bib43","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1186\/s12885-023-11290-7","article-title":"CDK4\/6 inhibitors, PI3K\/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis","volume":"23","author":"Ji","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejmech.2025.118192_bib44","article-title":"Discovery of CDK\u2013HDAC dual inhibitors with potent anticancer activity","volume":"154","author":"Niu","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118192_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202300281","article-title":"Discovery of a dual-target inhibitor of CDK7 and HDAC1 that induces apoptosis and inhibits migration in colorectal cancer","volume":"18","author":"Chen","year":"2023","journal-title":"ChemMedChem"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:59:06Z","timestamp":1773122346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425009572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":45,"alternative-id":["S0223523425009572"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118192","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and synthesis of novel cyclin-dependent kinase 4\/6(CDK4\/6) and histone deacetylase (HDAC) dual inhibitors: In vitro and in vivo anticancer activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118192","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118192"}}